Celltrion has announced that the European Medicines Agency (EMA) has accepted for review an extension marketing authorization application for a subcutaneous formulation of the company’s biosimilar infliximab, CT-P13 (sold in Europe as Remsima and in the United States as Inflectra).
Celltrion has announced that the European Medicines Agency (EMA) has accepted for review an extension marketing authorization application for a subcutaneous formulation of the company’s biosimilar infliximab, CT-P13 (sold in Europe as Remsima and in the United States as Inflectra). The company says that it expects the EMA’s Committee for Medicinal Products for Human Use to deliver an opinion on the proposed formulation in the second half of 2019.
Celltrion is unique among biosimilar developers in that it has been pursuing a strategy to develop biosimilars of existing formulations of intravenously delivered biologics while simultaneously developing easier-to-use, patient-administered subcutaneous versions of the same biosimilars. These formulations, it says, will largely serve patients who are currently being successfully treated with originator biologics but who would benefit from being able to self-administer their therapies instead of traveling to infusion centers for administration.
In September of this year, Celltrion announced that it had completed its phase 3 clinical trial of the subcutaneous formulation. During the 2018 European League Against Rheumatism's Annual European Congress of Rheumatology, researchers reported that the subcutaneous formulation had similar efficacy and generally similar safety to the currently approved intravenous product in patients with rheumatoid arthritis.
Separately, Celltrion revealed positive results from a phase 1 study comparing the subcutaneous formulation to the approved formulation in patients with Crohn disease, and the study’s authors wrote that pharmacokinetic and pharmacodynamic modeling based on the comparable efficacy and safety results in the study suggest that the subcutaneous and intravenous doses of CT-P13 are similar.
If the company is successful in securing a marketing authorization for this formulation of its product, Celltrion will the sole developer to market a subcutaneous infliximab option.
Meanwhile, reference product sponsors have been pursuing approval for subcutaneous formulations of their own drugs in a bid to secure their market share for a variety of therapeutic areas. Roche, together with Halozyme, has successfully developed a subcutaneous version of its reference trastuzumab, Herceptin.
Roche has also developed a subcutaneous formulation of its brand-name rituximab, Rituxan, though the subcutaneous version of the drug that treats a variety of malignant and nonmalignant conditions is only approved in the United States, European Union, and other regulatory territories for the treatment of leukemia and lymphoma.
Study: More Biosimilar Competition Is Not Lowering Patient OOP Costs
March 29th 2024Despite more biosimilars entering the market and generating significant savings for payers and health care systems, these savings are not resulting in lower out-of-pocket (OOP) costs for patients, according to a recent study.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Physician and Patient Perspectives After Starting or Switching to Amgevita in IBD
March 23rd 2024A real-world study surveying physicians and patients on adalimumab biosimilar ABP 501 (Amgevita) in inflammatory bowel disease (IBD) found both patients initiating ABP 501 and those who had switched from the reference product had higher satisfaction levels.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
AAD Posters Examine Clinical Effects of Switching to Ustekinumab, Adalimumab Biosimilars
March 20th 2024Two posters presented at the American Academy of Dermatology (AAD) annual meeting examined the effects of switching from reference ustekinumab and adalimumab to biosimilar versions in patients with different types of psoriasis.
Webinar Addresses Solutions to Improve Adalimumab Biosimilar Uptake
March 18th 2024Government policies, including those related to prescribing incentives and interchangeability, need to be reworked to encourage biosimilar adoption and create meaningful savings for health systems, according to speakers at a recent webinar.